Financial Comparison: Amylyx Pharmaceuticals (AMLX) vs. Its Competitors

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Amylyx Pharmaceuticals to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.

Valuation & Earnings

This table compares Amylyx Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Amylyx Pharmaceuticals $87.37 million -$144.74 million -18.27
Amylyx Pharmaceuticals Competitors $688.64 million $7.69 million -18.43

Amylyx Pharmaceuticals’ competitors have higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Amylyx Pharmaceuticals has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals’ competitors have a beta of -1.86, suggesting that their average share price is 286% less volatile than the S&P 500.

Profitability

This table compares Amylyx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amylyx Pharmaceuticals N/A -41.54% -38.91%
Amylyx Pharmaceuticals Competitors -12,224.75% -204.85% -31.52%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Amylyx Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals 1 0 6 2 3.00
Amylyx Pharmaceuticals Competitors 9941 15335 45756 1605 2.54

Amylyx Pharmaceuticals presently has a consensus price target of $43.71, suggesting a potential upside of 66.15%. As a group, “Biotechnology” companies have a potential upside of 134.44%. Given Amylyx Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Amylyx Pharmaceuticals has less favorable growth aspects than its competitors.

Summary

Amylyx Pharmaceuticals beats its competitors on 8 of the 13 factors compared.

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.